Global Amlodipine Besylater Drug Market Industry Share, Size: 2022 Market Research with Growth, Manufacturers, Segments and Forecast – 2028

The global amlodipine besylater drug market is anticipated to grow at a CAGR of 3.5% during the forecast period (2022-2028). Amlodipine besylater is used for the treatment of high blood pressure in adults. This drug is given with other combination drugs and also alone depending on the condition. This drug is also given in case of angina in which severe chest pain occurs. Coronary artery disease is a condition in which the blood vessels which supply blood from different parts of the body to the heart start to narrow down. This medication comes under calcium channel blockers. It works on the blood vessels which carry blood to the heart by relaxing them. Due to high blood pressure, serious health conditions occur such as brain hemorrhage, damage to blood vessels, heart failure, kidney failure stroke, and so on. Doctors advise a change in lifestyle along with this drug.

An increase in drug approvals by agencies to give more alternatives in therapeutics is expected to drive the market during the forecast period. For instance, in Nov 2021, Central Drugs Standard Control Organization and its subsidiary agency Subject Expert Committee has approved the phase 3 clinical trial of amlodipine besylate USP with  Amlodipine 10mg and Olmesartan medoxomil USP 40 mg. This drug will be manufactured by Torrent Pharmaceuticals.

Some major players in the market include Pfizer Inc., Mylan NV, and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in Mar 2020, Kitov Pharma Ltd. which works in designing therapies for tumor evasion has announced that it is going to launch the Consensi drug in the US. This drug is a combination of celecoxib and amlodipine besylate. It is manufactured for the treatment of osteoarthritis and high blood pressure. This drug was passed by the US Food and Drug Administration to start its marketing. Kitov Pharma Ltd. is expected to receive around $99.5 million in terms of reimbursement payments and royalties. It would also receive around $28 million and $36 million between 2020 and 2022. This amount would be for extra royalty.

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028
  • Segment Covered-
    • By Disease
    • By End-User
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Competitive Landscape- Pfizer , Mylan NV, and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?
    • Deviation from the pre-COVID-19 forecast
    • Most affected region and segment
  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Amlodipine Besylater Drug Market Report By Segment

By Disease

  • Blood Pressure
  • Coronary Artery Disease
  • Angina

By End-User

  • Hospital
  • Clinic
  • Others

Global Amlodipine Besylater Drug Market Report By Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

 

The report will be delivered within 48-72 hours after payment confirmation